AR044029A2 - Ritonavir amorfo, procesos para su preparacion y procesos para la preparacion de la forma polimorfa cristalina i de ritonavir sustancialmente pura - Google Patents

Ritonavir amorfo, procesos para su preparacion y procesos para la preparacion de la forma polimorfa cristalina i de ritonavir sustancialmente pura

Info

Publication number
AR044029A2
AR044029A2 ARP040101329A AR044029A2 AR 044029 A2 AR044029 A2 AR 044029A2 AR P040101329 A ARP040101329 A AR P040101329A AR 044029 A2 AR044029 A2 AR 044029A2
Authority
AR
Argentina
Prior art keywords
processes
ritonavir
preparation
substantially pure
polymorm
Prior art date
Application number
Other languages
English (en)
Inventor
A Saleki-Gerhardt
J Bauer
B Narayanan
S Chemburkar
K Patel
P Bauer
K Allen
H Spiwek
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26817251&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR044029(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of AR044029A2 publication Critical patent/AR044029A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28—Radicals substituted by nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Steroid Compounds (AREA)

Abstract

Ritonavir amorfo sustancialmente puro, caracterizado por una transición vítrea desde alrededor de 45ºC a alrededor de 49ºC. También se describen procesos para su preparación y los procesos para preparar la Forma polimorfa cristalina I de ritonavir sustancialmente pura. Estos compuestos son útiles como inhibidores de la proteasa del virus de la inmunodeficiencia humana (HIV).
ARP040101329 1998-07-20 2004-04-20 Ritonavir amorfo, procesos para su preparacion y procesos para la preparacion de la forma polimorfa cristalina i de ritonavir sustancialmente pura AR044029A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11934598A 1998-07-20 1998-07-20
US32609399A 1999-06-04 1999-06-04

Publications (1)

Publication Number Publication Date
AR044029A2 true AR044029A2 (es) 2005-08-24

Family

ID=26817251

Family Applications (5)

Application Number Title Priority Date Filing Date
ARP990103557 AR019431A1 (es) 1998-07-20 1999-07-20 POLIMORFO CRISTALINO DE (2S,3S,5S)-5-(N-(N-((N-METIL -N- ((2-ISOPROPIL-4-TIAZOLIL)METIL) AMINO)CARBONIL)-L-VALINIL)AMINO)-2-(N-((5-TIAZOLIL) METOXICARBONIL) AMINO-1,6-DIFENIL-3-HIDROXIHEXANO Y PROCESO PARA SU PREPARACIoN.
ARP040101329 AR044029A2 (es) 1998-07-20 2004-04-20 Ritonavir amorfo, procesos para su preparacion y procesos para la preparacion de la forma polimorfa cristalina i de ritonavir sustancialmente pura
ARP050102703 AR049658A2 (es) 1998-07-20 2005-06-29 Ritonavir amorfo, su uso en la fabricacion de un medicamento, composicion farmaceutica, proceso para su preparacion y proceso para la preparacion de la forma polimorfa cristalina i de ritonavir.
ARP070100928 AR059763A2 (es) 1998-07-20 2007-03-06 Proceso para la preparacion de la forma polimorfa cristalina i de ritonavir
ARP070100929 AR059764A2 (es) 1998-07-20 2007-03-06 Proceso para preparar una composicion farmaceutica de ritonavir y composicion que se obtiene

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP990103557 AR019431A1 (es) 1998-07-20 1999-07-20 POLIMORFO CRISTALINO DE (2S,3S,5S)-5-(N-(N-((N-METIL -N- ((2-ISOPROPIL-4-TIAZOLIL)METIL) AMINO)CARBONIL)-L-VALINIL)AMINO)-2-(N-((5-TIAZOLIL) METOXICARBONIL) AMINO-1,6-DIFENIL-3-HIDROXIHEXANO Y PROCESO PARA SU PREPARACIoN.

Family Applications After (3)

Application Number Title Priority Date Filing Date
ARP050102703 AR049658A2 (es) 1998-07-20 2005-06-29 Ritonavir amorfo, su uso en la fabricacion de un medicamento, composicion farmaceutica, proceso para su preparacion y proceso para la preparacion de la forma polimorfa cristalina i de ritonavir.
ARP070100928 AR059763A2 (es) 1998-07-20 2007-03-06 Proceso para la preparacion de la forma polimorfa cristalina i de ritonavir
ARP070100929 AR059764A2 (es) 1998-07-20 2007-03-06 Proceso para preparar una composicion farmaceutica de ritonavir y composicion que se obtiene

Country Status (30)

Country Link
EP (4) EP1097148B1 (es)
JP (4) JP4815050B2 (es)
KR (3) KR100793046B1 (es)
CN (5) CN1502613A (es)
AR (5) AR019431A1 (es)
AT (3) ATE261947T1 (es)
AU (1) AU768207B2 (es)
BG (4) BG65150B1 (es)
BR (1) BR9912010A (es)
CA (3) CA2674800A1 (es)
CO (1) CO5090830A1 (es)
CY (2) CY1111600T1 (es)
CZ (2) CZ298188B6 (es)
DE (2) DE69940616D1 (es)
DK (3) DK1097148T3 (es)
ES (3) ES2372990T3 (es)
HK (2) HK1037918A1 (es)
HU (3) HU227540B1 (es)
ID (1) ID27996A (es)
IL (4) IL140492A0 (es)
MY (2) MY121765A (es)
NO (2) NO318385B1 (es)
NZ (2) NZ509125A (es)
PL (2) PL194710B1 (es)
PT (3) PT1097148E (es)
SI (3) SI2017269T1 (es)
SK (3) SK287381B6 (es)
TR (1) TR200100171T2 (es)
TW (3) TWI362382B (es)
WO (1) WO2000004016A2 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6894171B1 (en) 1998-07-20 2005-05-17 Abbott Laboratories Polymorph of a pharmaceutical
MY121765A (en) * 1998-07-20 2006-02-28 Abbott Lab Polymorph of ritonavir
TR200103488T2 (tr) * 1999-06-04 2002-04-22 Abbott Laboratories Geliştirilmiş farmasötik formülasyonlar.
EP1395249A1 (en) * 2001-05-25 2004-03-10 Abbott Laboratories Soft elastic capsules comprising ritonavir and/or lopinavir
TWI286476B (en) * 2001-12-12 2007-09-11 Tibotec Pharm Ltd Combination of cytochrome P450 dependent protease inhibitors
US7205413B2 (en) 2002-05-03 2007-04-17 Transform Pharmaceuticals, Inc. Solvates and polymorphs of ritonavir and methods of making and using the same
US8377952B2 (en) * 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
BRPI0401742B8 (pt) 2004-05-13 2021-05-25 Cristalia Produtos Quim Farmaceuticos Ltda composto análogo do ritonavir útil como inibidor de protease retroviral, preparação do composto análogo do ritonavir e composição farmacêutica do composto análogo do ritonavir
US20080312300A1 (en) * 2005-05-30 2008-12-18 Yoginder Pal Sachdeva Processes for the Preparation of Stable Polymorphic Form I of Ritonavir
WO2008041176A2 (en) * 2006-10-03 2008-04-10 Ranbaxy Laboratories Limited Process for the preparation of form i and form ii of ritonavir
CN102898398B (zh) * 2011-07-27 2015-01-14 上海迪赛诺药业有限公司 一种制备i型利托那韦多晶型结晶的方法
US9370578B2 (en) 2012-03-07 2016-06-21 Ratiopharm Gmbh Dosage form comprising lopinavir and ritonavir
HUE027829T2 (en) 2012-03-07 2016-11-28 Ratiopharm Gmbh Dosage forms containing non-crystalline lopinavir and crystalline ritonavir
EP3038607A2 (en) 2013-08-29 2016-07-06 Teva Pharmaceutical Industries Ltd. Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir and a monolithic tablet comprising darunavir and ritonavir
CA2942877A1 (en) 2014-04-08 2015-10-15 Nitzan SHAHAR Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir
CN106749085B (zh) * 2016-12-23 2019-05-24 东北制药集团股份有限公司 一种制备利托那韦的方法
EP3569225A1 (en) 2018-05-18 2019-11-20 Pharmaceutical Oriented Services Ltd Solid dispersion containing ritonavir
RU2759544C1 (ru) * 2021-01-29 2021-11-15 Общество с ограниченной ответственностью "АМЕДАРТ" Твёрдая фармацевтическая композиция для изготовления перорального терапевтического средства для профилактики и/или лечения ВИЧ-инфекции

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5552558A (en) 1989-05-23 1996-09-03 Abbott Laboratories Retroviral protease inhibiting compounds
US5354866A (en) 1989-05-23 1994-10-11 Abbott Laboratories Retroviral protease inhibiting compounds
DK0727419T3 (da) * 1992-12-29 2002-06-10 Abbott Lab Mellemprodukter til fremstilling af forbindelser, som inhiberer retroviral protease
IL110752A (en) 1993-09-13 2000-07-26 Abbott Lab Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor
US5559158A (en) * 1993-10-01 1996-09-24 Abbott Laboratories Pharmaceutical composition
US5491253A (en) 1993-10-22 1996-02-13 Abbott Laboratories Process for the preparation of a substituted 2,5-diamino-3-hydroxyhexane
IL111991A (en) 1994-01-28 2000-07-26 Abbott Lab Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent
US5567823A (en) * 1995-06-06 1996-10-22 Abbott Laboratories Process for the preparation of an HIV protease inhibiting compound
US6037157A (en) * 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
US6160122A (en) 1996-06-28 2000-12-12 Abbott Laboratories Process for the preparation of a disubstituted thiazole
ZA9710071B (en) * 1996-11-21 1998-05-25 Abbott Lab Pharmaceutical composition.
MY121765A (en) * 1998-07-20 2006-02-28 Abbott Lab Polymorph of ritonavir
DE19856432A1 (de) * 1998-12-08 2000-06-15 Basf Ag Nanopartikuläre Kern-Schale Systeme sowie deren Verwendung in pharmazeutischen und kosmetischen Zubereitungen
TR200103488T2 (tr) * 1999-06-04 2002-04-22 Abbott Laboratories Geliştirilmiş farmasötik formülasyonlar.

Also Published As

Publication number Publication date
EP1097148B1 (en) 2004-03-17
CN1310715B (zh) 2010-11-03
ID27996A (id) 2001-05-03
DK2017269T3 (da) 2012-03-05
NZ509125A (en) 2003-02-28
CY1111600T1 (el) 2015-10-07
CZ2006533A3 (cs) 2001-05-16
CO5090830A1 (es) 2001-10-30
HU0800267D0 (en) 2008-06-30
ES2372990T3 (es) 2012-01-30
HU0800266D0 (en) 2008-06-30
JP2002520410A (ja) 2002-07-09
IL140492A0 (en) 2002-02-10
EP2017269A8 (en) 2009-09-30
WO2000004016A2 (en) 2000-01-27
CY1112139T1 (el) 2015-11-04
NZ522690A (en) 2004-04-30
HUP0103823A3 (en) 2003-05-28
PT1418174E (pt) 2009-06-08
EP2298751A3 (en) 2011-08-17
IL187181A0 (en) 2008-02-09
HU229999B1 (en) 2015-04-28
JP2014074047A (ja) 2014-04-24
CA2510949C (en) 2009-11-17
SK286388B6 (sk) 2008-09-05
KR100793046B1 (ko) 2008-01-10
SK922001A3 (en) 2001-07-10
EP1418174A2 (en) 2004-05-12
CN1502613A (zh) 2004-06-09
ATE425974T1 (de) 2009-04-15
AR059764A2 (es) 2008-04-30
EP1097148A2 (en) 2001-05-09
CN101259128A (zh) 2008-09-10
EP1418174B1 (en) 2009-03-18
JP5732212B2 (ja) 2015-06-10
NO20010298L (no) 2001-01-18
SI2017269T1 (sl) 2012-02-29
KR100740796B1 (ko) 2007-07-20
PL348033A1 (en) 2002-05-06
HUP0103823A2 (hu) 2002-02-28
SI1418174T1 (sl) 2009-08-31
IL191582A0 (en) 2008-12-29
DK1097148T3 (da) 2004-04-26
AU5003799A (en) 2000-02-07
BG110080A (bg) 2008-11-28
AR049658A2 (es) 2006-08-23
CA2337846C (en) 2006-02-21
AR019431A1 (es) 2002-02-20
CA2510949A1 (en) 2000-01-27
CN102153524A (zh) 2011-08-17
TR200100171T2 (tr) 2001-05-21
AU768207B2 (en) 2003-12-04
PL213978B1 (pl) 2013-05-31
JP4815050B2 (ja) 2011-11-16
TWI227713B (en) 2005-02-11
EP2017269A2 (en) 2009-01-21
HK1037918A1 (en) 2002-02-22
SI1097148T1 (en) 2004-10-31
DE69940616D1 (de) 2009-04-30
CN1310715A (zh) 2001-08-29
CA2674800A1 (en) 2000-01-27
BG65150B1 (bg) 2007-04-30
EP2017269A3 (en) 2009-06-10
PT1097148E (pt) 2004-05-31
BG109682A (bg) 2007-03-30
EP1418174A3 (en) 2004-06-23
BG65963B1 (bg) 2010-07-30
HU227540B1 (en) 2011-08-29
BG105197A (en) 2001-10-31
KR20040081137A (ko) 2004-09-20
NO327320B1 (no) 2009-06-08
SK287586B6 (sk) 2011-03-04
CA2337846A1 (en) 2000-01-27
IL187181A (en) 2009-09-01
JP2010270135A (ja) 2010-12-02
NO318385B1 (no) 2005-03-14
BR9912010A (pt) 2001-04-10
PT2017269E (pt) 2011-12-20
ES2214038T3 (es) 2004-09-01
JP2017061475A (ja) 2017-03-30
KR20010072003A (ko) 2001-07-31
CZ298188B6 (cs) 2007-07-18
DE69915628T2 (de) 2004-08-12
CZ307116B6 (cs) 2018-01-24
MY121765A (en) 2006-02-28
BG66140B1 (bg) 2011-07-29
EP2298751A2 (en) 2011-03-23
IL140492A (en) 2010-12-30
TWI362382B (en) 2012-04-21
IL191582A (en) 2016-02-29
HK1121155A1 (en) 2009-04-17
WO2000004016A3 (en) 2000-03-30
MY145265A (en) 2012-01-13
KR20060118022A (ko) 2006-11-17
NO20010298D0 (no) 2001-01-18
HU230150B1 (hu) 2015-09-28
TW200716550A (en) 2007-05-01
AR059763A2 (es) 2008-04-30
NO20042393L (no) 2001-01-18
PL194710B1 (pl) 2007-06-29
TWI271400B (en) 2007-01-21
CZ2001203A3 (en) 2001-05-16
DK1418174T3 (da) 2009-05-18
CN101966180A (zh) 2011-02-09
ES2322759T3 (es) 2009-06-26
SK287381B6 (sk) 2010-08-09
ATE534636T1 (de) 2011-12-15
EP2017269B1 (en) 2011-11-23
DE69915628D1 (en) 2004-04-22
ATE261947T1 (de) 2004-04-15
KR100853371B1 (ko) 2008-08-22
EP2017269A9 (en) 2009-10-14

Similar Documents

Publication Publication Date Title
AR044029A2 (es) Ritonavir amorfo, procesos para su preparacion y procesos para la preparacion de la forma polimorfa cristalina i de ritonavir sustancialmente pura
MXPA04006088A (es) Polimorfo de sulfato de hidrogeno de clopidogrel.
GT199900055A (es) Nuevas dihidropirimidinas2 heterocìclicamente sustituidas.
ECSP066539A (es) Derivados 1-amino-2-oxi sustituidos del tetrahidronaftaleno, procedimiento para su preparación y su uso como antiinflamatorio
HUP0401141A2 (hu) A fluvasztatin-nátrium kristályos formái, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
EA200200819A1 (ru) Кристаллическая форма ii линезолида
YU94103A (sh) Novi derivati sulfonske kiseline
AR024494A1 (es) Proceso para la preparacion de derivados de ciclopentano sustituido y novedosas estructuras cristalinas de los mismos
EA200300579A1 (ru) Соединение лактама
HN2002000334A (es) Procedimiento para la preparacion de derivados biciclicos sustituidos para el tratamiento del crecimiento celular anormal
ECSP003680A (es) Proceso para derivados del acido fenilacetico
PT1206452E (pt) Processo de preparacao de compostos benzoper-hidroisoindole
BR9810705A (pt) Processo para a produção de metacrilato de metila
CO4970800A1 (es) Forma termodinamicamente estable del acido (r)-3(((4-fluoro- fenil) sulfonil)amino)-1,2,3,4-tetrahidro-9h-carbazo-9-pro- panoico (ramatroban)
YU70502A (sh) Amorfna modifikacija torasemida
HUP0102124A2 (hu) Eljárás 2-acetiltio-3-fenil-propionsav és sói előállítására
EA200000172A3 (ru) Способ получения стимуляторов секреции гормонов роста
NO20032469L (no) Krystallisasjonsprosess for fremstilling av sterk konsentrert hydrogenperoksid
AR026453A1 (es) Procedimiento para la preparacion de cetiminas
PT1226135E (pt) Procedimento para a preparacao de um derivado do tiofeno
DE60222945D1 (de) Verfahren zur herstellung von cefpodoxim-proxetil
AU2003219423A1 (en) Process for the isolation of high purity crystalline citalopram base
ECSP003761A (es) Compuestos heterociclicos sililados
DE3887201D1 (de) Erythromycin-Derivate und ihre Herstellung und Verwendung.
AR029621A1 (es) Acidos aril sulfonicos como antagonistas fsh

Legal Events

Date Code Title Description
FC Refusal